Osteoporosis: The First 90 Days

Musculoskeletal · §162

You leave with a T-score and whatever the clinic prescribes first, usually a generic bisphosphonate. Fine for most; for the highest-risk it is the wrong opening move, and the window to fix it is about ninety days. The drug order decides how much bone you keep: build first and lock the gain in, or preserve first and cap what a builder can do later. A broken hip at 75 kills one in four within a year Brauer 2009; the sequence buys your way out.

Decide · Course Evidence Strong Chapter Musculoskeletal

The two classes work opposite ends of one loop. Bone-preservers (bisphosphonates like alendronate and zoledronic acid, plus denosumab) turn down the cells that dig out old bone ¹. Bone-builders (teriparatide, abaloparatide, romosozumab) drive the cells that lay down new bone, opening a roughly one-year window where the skeleton actively builds ². Fill that window, then a preserver locks it in; never open it, and the gain is lost.

The endpoint is actual broken bones, not scan numbers. A once-yearly zoledronic acid infusion takes about 70% off spine fractures and 41% off hip fractures over three years ³; denosumab is similar ¹. But for the very-high-risk, building first wins: a year of romosozumab then alendronate cut hip fractures 38% more than two straight years of alendronate ⁴. The guidelines now say the same: builder first for very-high-risk ⁵.

The ninety days do three jobs in order: confirm, stratify, start.

Days 0–30, find a cause. One in three to four cases has a treatable driver underneath, and cheap standard labs catch most: calcium, vitamin D, parathyroid hormone, thyroid, kidney, blood count, 24-hour urine calcium ⁵. Add a vertebral-fracture check on the DXA; one in five women over 70 has a silent one ⁶.
Days 30–60, size the real risk. Run FRAX, not the T-score alone ⁷. Very-high-risk means a T-score of −3.0 or below, a fracture in the last year, more than one ever, or a FRAX ten-year hip risk above 4.5%.
Very-high-risk, build first. Romosozumab 210 mg monthly for 12 months, or teriparatide/abaloparatide by daily self-injection up to 24 months. Then lock it in within a month of the last dose: zoledronic acid (yearly IV) or denosumab (every 6 months), or the new bone dissolves back out.
High-risk but below that line, preserve first. Alendronate 70 mg weekly, upright with water; or yearly zoledronic acid if the pill is a problem.
Everyone: calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day, resistance exercise, home fall-proofing, and a follow-up DXA at 12–24 months.

You will not feel any of this. There is no symptom to relieve; the payoff is an event that never arrives.

Weeks: turnover markers shift; the first dose may leave a day or two of flu-like aching.
Months 6–12: the fracture-risk curves separate from untreated, and a DXA on a builder shows a 13–15% spine gain ².
Years: the spine that did not collapse, the hip that did not break at 82, the Christmas at home instead of in rehab.

The fine print — when to skip it, and what people get wrong

The denosumab cliff: miss a dose and the gain rebounds into new spine fractures within a year ⁸; stopping it needs a zoledronic acid dose to lock the bone in ⁹. Stopping any builder without a follow-on preserver wastes it too ¹⁰.

Bisphosphonate-first is not always right: that was 2005 practice, before the builder trials ⁵. Calcium and vitamin D support the drug but do not replace it ⁶. And it is not a women's disease: a third of hip fractures over 50 are in men ⁶.

Romosozumab carries a boxed heart-attack and stroke warning; avoid it within a year of either ⁴. Bisphosphonates are skipped in poor kidney function and active oesophageal disease; their jaw and thigh-fracture risks are rare against the fracture risk treated ¹¹.

References

1Cummings et al. (2009). Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. link
2Cosman et al. (2016). Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. link
3Black et al. (2007). Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine. link
4Saag et al. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine. link
5Camacho et al. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update. Endocrine Practice. link
6LeBoff et al. (2022). The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International. link
7Kanis et al. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International. link
8Cummings et al. (2018). Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. Journal of Bone and Mineral Research. link
9Tsourdi et al. (2021). Discontinuation of Denosumab Therapy for Osteoporosis: A Systematic Review and Position Statement by ECTS. Bone. link
10Cosman F (2017). Anabolic Therapy and Optimal Treatment Sequences for Patients with Osteoporosis at High Risk for Fracture. Endocrine Practice. link
11Khosla S, Hofbauer LC (2017). Osteoporosis treatment: recent developments and ongoing challenges. The Lancet Diabetes & Endocrinology. link

Related in the handbook (15)

Works well with

— Carrying heavy loads loads the skeleton too, and that mechanical stress is part of keeping bone from thinning further.
— Paired with resistance training, daily creatine slows the bone loss this protocol is fighting.
— The estrogen drop at menopause is a major bone-loss driver; HRT started in time protects the skeleton.
— Weight-bearing loading like rucking is one of the bone-stimulating habits that supports bone density.
— Progressive resistance training is the exercise side of protecting bone after an osteoporosis diagnosis.
— Resistance training is the exercise prescription for protecting bone density, especially through menopause.
— Correcting a vitamin D shortfall is one of the basics underneath any osteoporosis plan.
— Vitamin K2 is one of the quiet, decade-scale supports for keeping bone density up.

Undermines

— Smoking speeds bone loss and slows fracture healing. Quitting is part of any serious bone plan.
— Years on a daily acid blocker quietly raise fracture risk — worth flagging while you size up bone loss.
— Too much preformed vitamin A (retinol from supplements and liver) weakens bone over time — worth auditing if you're managing osteoporosis.

— When heavy lifting risks fragile bones, restriction training is a lighter way to hold onto muscle.
— Undiagnosed celiac is a fixable cause of early bone loss; malabsorption is worth ruling out.
— Bone loss speeds up sharply in this transition — a silent part of the map worth getting a baseline scan for.
— Rapid weight loss on GLP-1 drugs strips bone along with fat, so fragile bones need the protein-and-lifting plan even more.